F. Hoffmann-La Roche AG shared on Thursday that the initial phase of its medication CT-388 showed positive results in treating patients dealing with obesity or type 2 diabetes.
"The results are highly encouraging for further development of CT-388 for both obesity and type 2 diabetes and underscore its potential to become a best-in-class therapy with durable weight loss and glucose control," Roche's Chief Medical Officer and Head of Global Product Development Levi Garraway said.
The study said that the treatment was "well-tolerated" with mild to moderate gastrointestinal-related adverse effects being the most common.
